California Public Employees Retirement System lowered its stake in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 51.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 213,166 shares of the biotechnology company’s stock after selling 222,366 shares during the quarter. California Public Employees Retirement System owned 0.15% of ZIOPHARM Oncology worth $1,326,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in ZIOPHARM Oncology by 12.9% in the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in ZIOPHARM Oncology by 50.0% in the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares during the last quarter. BB&T Securities LLC purchased a new stake in ZIOPHARM Oncology in the second quarter worth approximately $112,000. Principal Financial Group Inc. boosted its holdings in ZIOPHARM Oncology by 7.5% in the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new stake in ZIOPHARM Oncology in the second quarter worth approximately $162,000. Institutional investors own 41.86% of the company’s stock.

Several brokerages recently issued reports on ZIOP. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, HC Wainwright restated a “buy” rating and issued a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $16.25.

ILLEGAL ACTIVITY NOTICE: “California Public Employees Retirement System Reduces Position in ZIOPHARM Oncology Inc (ZIOP)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/08/california-public-employees-retirement-system-reduces-position-in-ziopharm-oncology-inc-ziop.html.

Shares of ZIOPHARM Oncology Inc (ZIOP) opened at $4.66 on Wednesday. ZIOPHARM Oncology Inc has a fifty-two week low of $4.34 and a fifty-two week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. sell-side analysts predict that ZIOPHARM Oncology Inc will post -0.55 earnings per share for the current fiscal year.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.